The pressures placed on pharmaceutical and biotechnology firms are causing companies to outsource their drug discovery processes as contract research organisations (CROs) expand to offer services such as finance/accounting, logistics and human resources and IT. Soaring costs of drug development and lengthy drug discovery times are well-established problems in the pharmaceutical industry, with only